Nonglycemic effects of dipeptidyl peptidase-4 inhibitors

被引:0
作者
Ametov, A. S. [1 ]
Kamynina, L. L. [1 ]
机构
[1] Russian Med Acad Postgrad Educ, Minist Hlth Russia, Moscow, Russia
关键词
type 2 diabetes mellitus; dipeptidyl peptidase-4 inhibitors; sitagliptin; nonglycemic effects; IV INHIBITION; SITAGLIPTIN; PIOGLITAZONE; EFFICACY; RAMADAN; INSULIN; SAFETY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The review considers the major nonglycemic effects of dipeptidyl peptidase-4 inhibitors commonly used in diabetological practice, by using as an example sitagliptin, the first and most investigated representative of this class.
引用
收藏
页码:98 / 102
页数:5
相关论文
共 32 条
[1]   The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial [J].
Al Sifri, S. ;
Basiounny, A. ;
Echtay, A. ;
Al Omari, M. ;
Harman-Boehm, I. ;
Kaddaha, G. ;
Al Tayeb, K. ;
Mahfouz, A. S. ;
Al Elq, A. ;
Radican, L. ;
Oezesen, C. ;
Katzeff, H. L. ;
Musser, B. J. ;
Suryawanshi, S. ;
Girman, C. J. ;
Davies, M. J. ;
Engel, S. S. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (11) :1132-1140
[2]   Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial [J].
Arechavaleta, R. ;
Seck, T. ;
Chen, Y. ;
Krobot, K. J. ;
O'Neill, E. A. ;
Duran, L. ;
Kaufman, K. D. ;
Williams-Herman, D. ;
Goldstein, B. J. .
DIABETES OBESITY & METABOLISM, 2011, 13 (02) :160-168
[3]   Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency [J].
Chan, J. C. N. ;
Scott, R. ;
Ferreira, J. C. Arjona ;
Sheng, D. ;
Gonzalez, E. ;
Davies, M. J. ;
Stein, P. P. ;
Kaufman, K. D. ;
Amatruda, J. M. ;
Williams-Herman, D. .
DIABETES OBESITY & METABOLISM, 2008, 10 (07) :545-555
[4]   Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation [J].
Derosa, Giuseppe ;
Ragonesi, Pietro Dario ;
Fogari, Elena ;
Cicero, Arrigo Francesco Giuseppe ;
Bianchi, Lucio ;
Bonaventura, Aldo ;
Romano, Davide ;
Maffioli, Pamela .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 (02) :221-229
[5]   Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis [J].
Engel, S. S. ;
Williams-Herman, D. E. ;
Golm, G. T. ;
Clay, R. J. ;
Machotka, S. V. ;
Kaufman, K. D. ;
Goldstein, B. J. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (07) :984-990
[6]   Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat) [J].
Ferreira, Liliana ;
Teixeira-de-Lemos, Edite ;
Pinto, Filipa ;
Parada, Belmiro ;
Mega, Cristina ;
Vala, Helena ;
Pinto, Rui ;
Garrido, Patricia ;
Sereno, Jose ;
Fernandes, Rosa ;
Santos, Paulo ;
Velada, Isabel ;
Melo, Andreia ;
Nunes, Sara ;
Teixeira, Frederico ;
Reis, Flavio .
MEDIATORS OF INFLAMMATION, 2010, 2010
[7]   Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin [J].
Garg, Rajesh ;
Chen, William ;
Pendergrass, Merri .
DIABETES CARE, 2010, 33 (11) :2349-2354
[8]   Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure [J].
Gomez, Nelson ;
Touihri, Karim ;
Matheeussen, Veerle ;
Da Costa, Agnes Mendes ;
Mahmoudabady, Maryam ;
Mathieu, Myrielle ;
Baerts, Lesley ;
Peace, Aaron ;
Lybaert, Pascale ;
Scharpe, Simon ;
De Meester, Ingrid ;
Bartunek, Jozef ;
Vanderheyden, Marc ;
Mc Entee, Kathleen .
EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (01) :14-21
[9]   The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety [J].
Green, Jennifer B. .
POSTGRADUATE MEDICINE, 2012, 124 (04) :54-61
[10]   Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? [J].
Grieve, David J. ;
Cassidy, Roslyn S. ;
Green, Brian D. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (08) :1340-1351